TY - JOUR
T1 - Lasting Impact of Clostridium difficile Infection in Inflammatory Bowel Disease
AU - Anderson, Alyce
AU - Click, Benjamin
AU - Ramos-Rivers, Claudia
AU - Cheng, Debbie
AU - Babichenko, Dmitriy
AU - Koutroubakis, Ioannis E.
AU - Hashash, Jana G.
AU - Schwartz, Marc
AU - Swoger, Jason
AU - Barrie, Arthur M.
AU - Dunn, Michael A.
AU - Regueiro, Miguel
AU - Binion, David G.
N1 - Publisher Copyright:
© 2017 Oxford University Press. All rights reserved.
PY - 2017
Y1 - 2017
N2 - Background: Patients with inflammatory bowel disease are at an increased risk of Clostridium difficile infection (CDI), but the impact of CDI on disease severity is unclear. The aim of this study was to determine the effect of CDI on long-term disease outcome in a matched cohort of patients with inflammatory bowel disease. Methods: Patients who tested positive for infection formed the CDI-positive group. We generated a 1:2 propensity matched case to control cohort based on risk factors for CDI in the year before infection. Health care utilization data (emergency department use, hospitalizations, and telephone encounters), medications, laboratories, disease activity, and quality-of-life metrics were compared by CDI status. Results: A total of 198 patients (66 CDI and 132 matched controls) were included (56.6% women; 60.1% Crohn’s disease, and 39.9% ulcerative colitis). In the year of infection, having CDI was significantly associated with more steroid and antibiotic exposure, elevated C-reactive protein or erythrocyte sedimentation rate, low vitamin D, increased disease activity, worse quality of life, and increased health care utilization (all P , 0.01). During the next year after infection, patients with CDI continued to have increased exposure to CDI-targeted antibiotics (P , 0.001) and other antibiotics (P ¼ 0.02). They also continued to have more clinic visits (P ¼ 0.02), telephone encounters (P ¼ 0.001), and increased health care financial charges (P ¼ 0.001). Conclusions: CDI in inflammatory bowel disease is significantly associated with markers of disease severity, increased health care utilization and poor quality of life during the year of infection, and a 5-fold increase in health care charges in the year after infection (see Video Abstract, Supplemental Digital Content, http://links.lww.com/IBD/B658).
AB - Background: Patients with inflammatory bowel disease are at an increased risk of Clostridium difficile infection (CDI), but the impact of CDI on disease severity is unclear. The aim of this study was to determine the effect of CDI on long-term disease outcome in a matched cohort of patients with inflammatory bowel disease. Methods: Patients who tested positive for infection formed the CDI-positive group. We generated a 1:2 propensity matched case to control cohort based on risk factors for CDI in the year before infection. Health care utilization data (emergency department use, hospitalizations, and telephone encounters), medications, laboratories, disease activity, and quality-of-life metrics were compared by CDI status. Results: A total of 198 patients (66 CDI and 132 matched controls) were included (56.6% women; 60.1% Crohn’s disease, and 39.9% ulcerative colitis). In the year of infection, having CDI was significantly associated with more steroid and antibiotic exposure, elevated C-reactive protein or erythrocyte sedimentation rate, low vitamin D, increased disease activity, worse quality of life, and increased health care utilization (all P , 0.01). During the next year after infection, patients with CDI continued to have increased exposure to CDI-targeted antibiotics (P , 0.001) and other antibiotics (P ¼ 0.02). They also continued to have more clinic visits (P ¼ 0.02), telephone encounters (P ¼ 0.001), and increased health care financial charges (P ¼ 0.001). Conclusions: CDI in inflammatory bowel disease is significantly associated with markers of disease severity, increased health care utilization and poor quality of life during the year of infection, and a 5-fold increase in health care charges in the year after infection (see Video Abstract, Supplemental Digital Content, http://links.lww.com/IBD/B658).
KW - Clostridium difficile
KW - health care utilization
KW - inflammatory bowel disease
KW - propensity score
UR - http://www.scopus.com/inward/record.url?scp=85049848544&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85049848544&partnerID=8YFLogxK
U2 - 10.1097/MIB.0000000000001251
DO - 10.1097/MIB.0000000000001251
M3 - Article
C2 - 29084081
AN - SCOPUS:85049848544
SN - 1078-0998
VL - 23
SP - 2180
EP - 2188
JO - Inflammatory bowel diseases
JF - Inflammatory bowel diseases
IS - 12
ER -